After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
This is the first update to the original CTS communication distributed on July 6th. As previously co...